Study to evaluate persistence of antibodies after vaccination with meningococcal vaccine GSK134612

Subjects who the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol should be enrolled in the study.

• Written informed consent obtained from the parent(s) or guardian(s) of the subject.
• Healthy subjects as established by medical history and clinical examination before entering into the study.
• A male or female having completed the primary study 109670 and who was primed with the investigational or Meningitec™ vaccines.

Exclusion criteria for persistence study entry (i.e. Month 24, 36 or 48):

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the subject’s first visit.
• History of meningococcal disease.
• Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine outside of study 109670.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.
• Administration of immunoglobulins and/or blood products within the three months preceding the subjects first visit.
• Concurrently participating in another clinical study, within 30 days of study entry, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
• Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy. Additional exclusion criteria for booster vaccination (to be checked at Month 48):
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccination.
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• Hypersensitivity to any vaccine containing diphtheria toxoid or non-toxic diphtheria toxin protein and/or tetanus toxoid.
• History of hypersensitivity after previous administration of Meningitec or the investigational vaccines in study 109670.
• Hypersensitivity to latex.
• Planned administration/ administration of a vaccine not foreseen by the protocol within one month before and 30 days after the booster dose.
• Previous vaccination with any component of the vaccines within the last month.
• History of any neurological disorder or seizures (one episode of febrile convulsion does not constitute an exclusion criteria).
• Major congenital defects or serious chronic illness.
• Acute disease at the time of vaccination.